August 11, 2026
According to Shivani Zoting, who specializes in healthcare and pharmaceutical market research, with 5+ years of experience in market research and industry analysis, this research indicates that the diabetic retinopathy market is set to grow from USD ...
March 16, 2026
Based on our market forecasts, the U.S. AI-Driven diabetic retinopathy screening market was valued at USD 191.05 million in 2025 and is expected to grow from USD 231.59 million in 2026 to around USD 1308.85 million by 2035, expanding at a CAGR of 21....
August 19, 2026
According to Payal Rabde, who specializes in products and techniques used to control pain and discomfort during dental procedures, including local anesthetics, sedation systems, and related delivery devices, with 4+ years of experience in market rese...
February 27, 2026
Market insights predict the global North America diabetic foot ulcer treatment industry will increase from USD 1.27 billion in 2024 to USD 2.22 billion by 2034, achieving a CAGR of 5.74%. In 2024, the U.S. led the North American diabetic foot ulcer t...
April 21, 2026
Projections indicate that, the global diabetic neuropathy treatment market will increase from USD 4.71 billion in 2024 to USD 9.93 billion by 2034, experiencing a CAGR of 7.75% over the next 10 years. The diabetic neuropathy treatment market is expan...
April 21, 2026
According to market projections, the diabetic ketoacidosis treatment sector is expected to grow from USD 930.89 million in 2025 to USD 1426.15 million by 2035, reflecting a CAGR of 4.36%. The diabetic ketoacidosis treatment market due to rising...
January 15, 2026
Market insights predict the global diabetic foot ulcer treatment industry will increase from USD 5.85 billion in 2025 to USD 10.52 billion by 2035, achieving a CAGR of 6.04%. A lot of factors contribute to the growing number of diabetic patients. One...
July 23, 2026
According to Payal Rabde, who specializes in the development , manufacturing, and commercialization of medications, including insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, metformin, sulfonylureas, and other oral antidiabetic...